Protalix BioTherapeutics (PLX) 10-Q2020 Q1 Quarterly report

Filed: 1 Jun 20, 7:08am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accredited, affectour, aforementioned, allantoin, amelioration, anAccounting, andBRIDGE, andBRIGHT, area, AUC, Baylor, bear, Boardissued, CAGR, capable, China, circulation, clear, clearance, Codification, cohort, College, combined, committed, comprehensive, contact, contractual, corona, correlation, creation, curve, deducting, Derralynn, discount, distancing, distinct, Dr, easily, effort, Eighteen, emerge, encoding, engineering, ensure, epidemic, EPS, equivalent, exemption, feasibility, fighting, Florida, Gout, grow, handle, higher, hospital, Hyatt, hypersensitivity, IIIBALANCE, IIIBRIDGE, IIIBRIGHT, inclusion, industry, instructed, interdependent, interrelated, iPSP, isdesigned, issuance, judgment, Kirin, learn, light, line, London, long, methodology, narrowing, nourishment, ofFabrazyme, official, ofMarch, opportunity, Orlando, ourBALANCE, ourBRIDGE, outbreak, Oxidase, pandemic, PEGylated, post, postpone, Praha, presence, prolonged, PTC, pursuit, quantitative, Raphael, raw, RCT, reaction, Regency, revaluation, reversal, reverse, Schiffmann, Scott, separately, serving, showed, simplified, single, slightly, social, split, spread, staffing, strain, subset, succeeded, succeeding, suspension, symptomatic, theBALANCE, theBALANCEStudy, thebridge, theBRIDGEStudy, theBRIGHT, theFinancial, Thephase, tissue, topline, tulinercept, UK, uncertain, Updatethat, Urate, uric, Uricase, variable, variety, White, withdrew, withFabrazymefor, WORLDSymposium, Wuhan

Removed: acquiring, affecting, antiTNF, apply, assist, ASU, beginning, biotechnology, Board, carryforward, classification, commercializingalfataliglicerase, denominated, detailed, devaluation, earlier, ending, expend, extended, FASB, firm, fulfillment, generate, improving, inventory, lease, leased, lessee, longer, LPS, maturity, monthly, nonemployee, package, pattern, permitted, portion, practical, recently, recognition, record, regularly, rental, require, restate, retrospective, scheduled, scope, secure, September, subsequently, substantial, transition, unsatisfied

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PLX transcripts

PLX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

PROTALIX BIOTHERAPEUTICS, INC.

CERTIFICATION

In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: June 1, 2020

/s/ Eyal Rubin
Eyal Rubin
Senior Vice President and Chief Financial Officer